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DOI: 10.1039/c0sm01371dMicroparticles with homogeneous properties are crucial for pharmaceutical applications where the
prior knowledge of exact drug loading and release behaviour is essential to achieve targeted therapeutic
goals. Various methods such as membrane microemulsion or templating to assemble uniform particles
often involve multiple steps, including post-processing for purification and recovery, with additional
chemical reactivity is often required to form solid particles, rendering less flexibility in the procedure.
Spray drying is a common method to produce pharmaceutical particles, although control over the
particle properties poses a challenge. Here we used a specially designed dryer utilising a micro-fluidic-
aerosol-nozzle to atomize monodisperse droplets from a range of precursors, to generate uniform
microparticles for controlled release applications. The versatility of the device enabled microparticles
with easily tunable drug release kinetics to be assembled by adjusting the drying conditions or the
composition of the precursors, including the use of dopants or different solvents. Significant adjustment
of the release profiles could be realized by manipulating the microstructure of the microparticles. Due
to the homogeneity of the particles, a direct correlation between the microstructural properties and
release mechanisms could be obtained, the knowledge of which is crucial for the design of spray-dried
polymeric-based pharmaceutical particles.Introduction
Particulate-based carriers in micro- and nano-scale play impor-
tant roles in therapeutic and diagnostic applications,1,2 due to the
potential benefits such as increased bioavailability, reduced risk
of systemic toxicity, and low probability of causing local irrita-
tion in comparison to conventional (monolithic) formulations.
When used in the oral dosage form, particulates are less affected
by gastric emptying, reducing the variation in gastrointestinal
transit time.3 At the same time, behaviors such as degradation,
uptake, and clearance of particulates are closely related to their
size and shape.4–6 Thus, polydisperse particles might induce
irreproducible release behavior with varying functionalities.6
There are several approaches to fabricate uniform particles,
including membrane emulsification,7 hydrogel template,8
acoustic excitation,9 and electrospraying.6,10 Often these methods
involve intricate steps and long operation time before obtaining
the final formulation.11 Post-processing such as the washing and
purification stages also lead to low loading efficiency that isaDepartment of Chemical Engineering, Monash University, Clayton, VIC,
3800, Australia. E-mail: cordelia.selomulya@monash.edu; Fax: 61 3
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This journal is ª The Royal Society of Chemistry 2011highly undesirable for expensive therapeutic agents. These issues
restrict the feasibility for clinical trials or large scale produc-
tion.11 Thus there is an urgent need for a robust process to
produce uniform microparticles with controllable functional-
ities.12
Here we demonstrated the preparation of uniform micropar-
ticles via a modified spray drying technique. Spray drying is ideal
to form particles in a single step, with feasibility for large-scale
production, and applicability for both hydrophilic and hydro-
phobic materials. It does not require further washing steps, while
any harsh chemical reactions for particle solidification can be
avoided.11,13 The inherent drawback for conventional spray
drying is that the atomizers generally produce polydisperse
droplets with different sizes and trajectories. These droplets then
experience various drying profiles within the same environment,
resulting in poor reproducibility over particle properties and
functionalities from batch-to-batch operation (or even from the
same batch). We have previously reported the methodology to
produce photoluminescent microcomposites, by ensuring iden-
tical drying experience for every individual droplet into solid
particles.14 Here we used the same versatile approach to fabricate
microparticles with uniform properties for controlled drug
release applications. The novelty of this study lies in the ability to
directly manipulate the microstructure of the polymeric micro-
particles to control the drug release mechanisms, made possible































































View Onlinestep from a relatively complex range of precursors. Polymeric
aqueous dispersion is employed as the basic excipient for particle
formulation, which offers advantages including (1) the extra
flexibility of the polymer state that can be tuned from the solvent
composition and (2) the possibility to eliminate the use of organic
solvents. Eudragit RS 30D is used as a model polymer
dispersion with the chemical structure shown in Fig. 1, sche-
matically representing their physicochemical behaviors in
different solvent systems.15,16 Vitamin B12 is used as a hydrophilic
model drug to test the controlled release properties of the
microparticles with distinct microstructures.Experimental section
Materials
Eudragit RS 30D (30% aqueous dispersion) was kindly
provided by Evonik Degussa Industries (Australia). Vitamin B12
(VB12), chitosan (low molecular weight) and tetraethoxysilane
(TEOS) were purchased from Sigma-Aldrich (Australia).
Acetone and absolute ethanol were of analytical grade from
Merck (Australia). All other reagents used were of analytical
grade. Deionized water (Milli-Q) was used for all precursor
preparation.Precursor preparation
The precursors for spray drying were prepared by directly
dispersing Eudragit RS 30D into certain solvents. To investi-
gate the effects of solvents and dopants, different formulations of
precursors were prepared (Table 1). Calculated amounts of chi-
tosan and TEOS were added to reach 0.5% (w/v). The total mass
content of excipients was set to be 3% (w/v). The dissolution of
chitosan and hydrolysis of TEOS were facilitated in an acidic
medium. Certain amount of VB12 was added with drug: excipi-
ents ratio of 5%.Fig. 1 (a) Chemical structure of Eudragit RS; Eudragit RS, which is
insoluble in water but dissolves in organic solvents, has different physi-
cochemical behaviors within different solvents: (b) exists as polymeric
nano-dispersions in aqueous medium, (c) exists as polymer solutions in
organic solvents.
3324 | Soft Matter, 2011, 7, 3323–3330Microparticles fabrication
Monodisperse droplets were generated from precursor solution
by a micro-fluidic aerosol nozzle system, with an orifice diameter
of 75 mm. Briefly, the precursor solutions were fed into a stan-
dard steel reservoir and dehumidified instrument air was used to
force the liquid in the reservoir to jet through the nozzle. The
liquid jet was broken into droplets by disturbance from vibrating
piezoceramics. The droplet formation mode was monitored by
a digital SLR camera (Nikon, D90) with a speed-light (Nikon
SB-400) and a micro-lens (AF Micro-Nikkor 60mm f/2.8D). The
liquid flow rate and applied disturbance frequency were adjusted
to best achieve monodisperse droplet formation.17 These mono-
disperse droplets obtained were well dispersed and dried at
a specific drying temperature (ESI†, Fig. S1). In a typical
experiment, the drying temperature of 180 C was used.
Temperatures of 130 C and 155 C were also set to investigate
the influence of drying temperature on microparticle character-
istics and drug release behaviors.Particle characterization
Images of microparticles were recorded by light microscopy
(Motic B1-223A, UK). Particle size and size distribution were
analyzed using the software package Motic Images Plus 2.0 ML






and the span of size distribution was described as
span ¼ ðd90  d10Þ
d50
, where di was the diameter of the i-th particle,
N was the total number of particles counted, d90, d50, d10 were the
cumulative particle sizes at 90%, 50%, and 10%, respectively. The
morphology and structure of microparticles before and after
the drug release test were characterized by field-emission scan-
ning electron microscopy (FESEM, JEOL 7001F, Japan). FT-IR
spectrum was performed on a Perkin Elmer spectrometer in the
wavelength range of 4000–400 cm1, at a spectral resolution of
4 cm1. Differential scanning calorimetry (DSC) was determined
with a TA-Q100 DSC. The DSC tests were conducted over
a temperature range from 0 to 150 C at 10 C min1 under a dry
nitrogen flow (50 mL min1).In vitro drug release test
In a typical experiment, the drug-loaded microparticles (50 mg)
were weighted into 100 mL conical flask, and 50 mL of PBS
(phosphate buffer solution) release medium (pH 7.4) was trans-
ferred into the flask. Due to the solubility of chitosan at acidic
condition, the release test for microparticles containing chitosan
was also conducted at pH 1.2 using HCl solution. The flask was
kept in a shaking incubator at 37 C with constant agitation
(100 rpm) for the duration of the release test (28 hours). At
certain time intervals, 1 mL of the release medium was with-
drawn from the flask and replaced with the same amount of fresh
release medium. Collected samples were transferred into 1.7 mL
microtubes, centrifuged for 5 min at 10 000 rpm (Heal force,
Neofuge 23R) and subjected to assay immediately. The content
of VB12 in the sample was determined by a microplate reader
(SpectraMax M2e, Molecular devices) at the wavelength ofThis journal is ª The Royal Society of Chemistry 2011
Table 1 Formulations of precursors for spray drying
Formulation no. Eudragit RSa (w/v) Solvent compositionb Chitosan (w/v) TEOS (w/v) Vitamin B12 (w/w) Vitamin B12 loading (%)
R3(H) 3% H — — 5% 97.10  1.09
R3(H1A2) 3% H : A ¼ 1 : 2 — — 5% 96.01  0.95
R3(H1A2E0.5) 3% H : A : E ¼ 1 : 2: 0.5 — — 5% 97.27  1.18
R2.5C0.5(H) 2.5% H 0.5% — 5% 97.28  1.95
R2.5T0.5(H) 2.5% H — 0.5% 5% 96.15  2.79
a e.g. 10 mL Eudragit RS 30D was added into 90 mL deionized water to get a 3% (w/v) Eudragit RS precursor. b H, A, and E were short for H2O,































































View Onlinemaximum absorbance (361 nm). Each sample was performed in
triplicate.
The total amount of VB12 loaded into microparticles was
determined by dissolving an accurately weighed amount of
microparticles in 1 mL ethanol (or mixture of ethanol and acidic
acid/NaOH solution for R2.5C0.5(H) and R2.5T0.5(H) particles,
respectively). After the dissolution of particles, the solutions were
centrifuged for 5 min at 10 000 rpm and the amount of VB12 in
supernatant was determined by the microplate reader under
361 nm. The loading efficiency of VB12 was calculated by
dividing the amount of drug in the microparticles by the initial
amount of drug added.Results and discussion
Fabrication of uniform microparticles
The quality of the initial droplets was a prerequisite to obtain
homogenous microparticles.18 Fig. S2 (ESI†) showed the
photographs of the droplets generation process, indicating the
uniformity of the initial droplets. The size and morphology of
spray-dried microparticles were also confirmed by SEM images
(Fig. 2 and 3). The particle size distributions were summarized in
Fig. 4, revealing narrow size distributions for all samples. The
homogenous properties suggested that every individual droplet
experienced a similar drying process in the dryer chamber, so that
any added drugs in the precursors would be incorporated equally
into each microparticle of the same size and morphology.19 The
drug loading efficiency for each sample was summarized in
Table 1, indicating the high (close to 100%) drug loading of
spray-dried microparticles. The loading efficiency was signifi-
cantly higher than those attainable with wet chemistry-based
methods (typically with loading efficiency of less than 50%),8,20
due to losses of encapsulated ingredients during the washing
steps.Fig. 2 SEM photographs of R3(H) microparticles fabri
This journal is ª The Royal Society of Chemistry 2011Particle morphology
All microparticles obtained in this study generally exhibited pot-
like shapes (round or wrinkled). The SEM photographs of R3(H)
(Fig. 2) showed that the microparticles were pot-like with rela-
tively smooth surface. The hollow structure was confirmed by
SEM image (ESI†, Fig. S3). Microparticles obtained from
different drying temperature displayed similar morphology,
indicating that the drying temperature (in the range investigated
here) had little effect on the shapes of spray-dried microparticles.
Under the same operating conditions, different shaped
microparticles were observed when different types of solvent
were used (Fig. 2, 3A and B). In particular, by changing the
composition of solvent from H2O (100%) to a mixture of H2O
and acetone with a ratio of 1 : 2, the shape was significantly
deformed with the wrinkling of the particle surface. This was due
to the difference in boiling points and specific heat capacities of
the different solvents, which induced different latent heat of
evaporation and drying rates. A faster drying rate resulted in
shorter drying time and more extreme drying behavior (i.e. faster
heat and mass transfers). Thus the tendency to deform for these
droplets was increased during the more vigorous drying
process.21,22 The boiling points and specific heat capacities of
solvents were in the following order: H2O > ethanol > acetone.
As expected, the deformation of microparticles was most notable
for R3(H1A2) which contained the highest amount of acetone.
Fig. 3C and D illustrated that different dopants could also
affect particle morphology. The round pot-shape was signifi-
cantly deformed with surface roughness enhanced when 0.5%
chitosan was incorporated. With the addition of 0.5% TEOS, the
particle shape was changed into a bowl-like morphology with
a large singular opening on the surface. It has been previously
reported that the morphology of spray-dried microparticles was
strongly dependent on the raw materials.1,22 Here we also
demonstrated this phenomenon by spray drying precursors
containing only 1% chitosan or 1% TEOS (Fig. 5) that showedcated at different temperatures. (Scale bar: 100 mm.)
Soft Matter, 2011, 7, 3323–3330 | 3325
Fig. 3 SEM photographs of the spray-dried microparticles: (A)
R3(H1A2), (B) R3(H1A2E0.5), (C) R2.5C0.5(H) and (D) R2.5T0.5(H). (Scale
bar: 100 mm.)
Fig. 4 Size distributions of the spray-dried microparticles (APS: average parti
(E) R2.5T0.5(H).
Fig. 5 SEM photographs of spray-dried microparticles of (A) 1% chi-
tosan and (B) 1% TEOS.































































View Onlinedistinctive surface textures and particle shapes. The morphol-
ogies obtained for R2.5C0.5(H) and R2.5T0.5(H) (Fig. 3C and D)
simply confirmed these effects of dopant addition (rough and
smooth textures from chitosan and TEOS, respectively) on the
resulting microparticles.cle size): (A) R3(H), (B) R3(H1A2), (C) R3(H1A2E0.5), (D) R2.5C0.5(H) and
This journal is ª The Royal Society of Chemistry 2011
Fig. 6 Cumulative in vitro release of VB12 from the spray-dried micro-
particles fabricated at different temperatures (inset showing release data
at initial time period).
Fig. 7 Schematic diagrams of the microstructure of spray-dried micro-
































































View OnlineEffects of drying temperature
The release profiles of VB12 from R3(H) microparticles fabri-
cated at different drying temperatures are shown in Fig. 6. The
drug release rate was slightly accelerated with the lower drying
temperature. The moisture contents of microparticles spray dried
at 180 C, 155 C, and 130 C were 4.32  0.13%, 4.94  0.13%,
and 5.35  0.14%, respectively. Given the same particle
composition and particle size, the different drug release rates
could be ascribed to different moisture contents of the micro-
particles. An increasing hydrophilic domain at higher moisture
content enhanced the permeability of microparticles, thus facil-
itating buffer penetration and faster drug release rate.23,24
After the initial burst release, the remaining drug was released
more evenly with the release rate decreasing with time. At the
initial release stage, the more rapid drug release was due to the
polymer water uptake and swelling accompanied by drug diffu-
sion as reported before.25 At the latter stage, drug diffusion
would become the main driving force for release due to less
availability of VB12 near the particle surface.
25Fig. 8 Cumulative in vitro release of VB12 from the spray-dried micro-
particles fabricated from different solvents.Effects of solvent
Since Eudragit RS has different physicochemical behaviors in
aqueous and organic based solvents, the type of solvent used
would have influenced the microstructures of the particles.11,25,26
The proposed microstructures fabricated from different solvents
were shown in Fig. 7A and B. Eudragit RS, as a water insoluble
polymer, existed in the form of nano-dispersion with H2O as
solvent. With partial replacement of acetone or ethanol, the
polymer which was soluble in acetone or ethanol dissolved, so
that the entanglement of molecular chains provided more
barriers for drug diffusion.
We confirmed the effects of solvent type by comparing the
release data for R3(H), R3(H1A2), and R3(H1A2E0.5) (Fig. 8).
Microparticles using water as solvent (R3(H)) released 80% of
total VB12 in 0.5 h and almost 100% within 5 h. With the
incorporation of acetone or ethanol, the initial burst effect andThis journal is ª The Royal Society of Chemistry 2011the subsequent release rate were effectively decelerated. As the
particles were fabricated under the same drying condition with
equal amount of VB12 and Eudragit RS polymer, the different
drug release profiles could only be attributed to the difference in
the physical state of the polymer due to the solvent and/or the
spatial distribution of VB12, as discussed in the latter section.
We also observed the morphology and surface texture of these
particles after the release test. Fig. 9 showed the morphology of
the original spray-dried microparticles (Fig. 9A0–C0), and after
the release test (Fig. 9A1–C1). There was no significant change
in the morphology of microparticles before and after drug release
for R3(H1A2) and R3(H1A2E0.5). However, small pores emerged
in R3(H) microparticles after the release of VB12 (Fig. 9A1). The
existence of pores after the release test also confirmed the packing
structure for R3(H) as proposed in Fig. 7A.
To confirm the hypothesis of the different physical states of
Eudragit RS for R3(H), R3(H1A2), and R3(H1A2E0.5), the
thermal properties of microparticles were analyzed with DSC.
The results from DSC test (Fig. 10) showed that the curvesSoft Matter, 2011, 7, 3323–3330 | 3327
Fig. 9 SEM photographs of the spray-dried microparticles fabricated from different solvents before (A0, B0, C0) and after (A1, B1, C1) drug release test:
(A) R3(H), (B) R3(H1A2), (C) R3(H1A2E0.5). (Scale bar of main picture: 10 mm; scale bar of inset: 2 mm.)
Fig. 10 DSC curves of the drug-loaded Eudragit RS microparticles
fabricated from different solvents.
Fig. 11 FT-IR spectrum of VB12 and VB12 loaded Eudragit RS micro-































































View Onlinestarted to rise from a similar temperature, with the shapes of
DSC thermograms for R3(H1A2) and R3(H1A2E0.5) similar to
each other. The peaks around 65 C were caused by the glass
transition of Eudragit RS.25,27 However the peak was extended
for the aqueous system of R3(H), with the maximum appearing
at about 100 C. In all three cases, the particle size was similar
(about 80–90 mm). It could be concluded that the difference in
DSC curves was solely due to the difference of the physical state
of the polymer, namely the packing of polymeric nanoparticles in
R3(H) and the polymer chains in R3(H1A2) and R3(H1A2E0.5).
Although the physical state of the polymer was proven to be
relatively similar for R3(H1A2) and R3(H1A2E0.5), the drug
release profiles of the microparticles were quite distinctive. To
explain this phenomenon, the different particle morphologies
should be considered. Fig. 9B0 and C0 indicated that the
microparticles of R3(H1A2) and R3(H1A2E0.5) displayed notice-
ably different shapes and surface characteristics. The deformed
shape and wrinkled surface of R3(H1A2) significantly increased
the surface area for similar size particles, thus allowing more
contact with the release medium. This result was consistent with
previous studies which reported that particles with smoother
surface displayed slower drug release characteristics.28,293328 | Soft Matter, 2011, 7, 3323–3330We also compared the FT-IR spectra of the microparticles
prepared using different solvent systems (Fig. 11). No significant
change was observed in the entire spectrum (thus confirming the
same composition for different microparticles), with two slight
deviations observed. Firstly, the two peaks around 1580
and 1625 cm1 in (R3(H)) almost disappeared for R3(H1A2) and
R3(H1A2E0.5). In addition, the two peaks around 1380 and
1400 cm1 for R3(H1A2) and R3(H1A2E0.5) combined into
a single peak for (R3(H). These peaks were the characteristic
peaks of VB12, and the relatively higher intensity of these peaks
in R3(H) indicated the higher amount of VB12 existing on or near
the particle surface.6,30 These data suggested that the fast initial
drug release rate of R3(H) microparticles could be directly linked
to the spatial distribution of VB12.Effects of dopants
The change in solvent composition has been proven to be an
effective way to tune the drug release profiles. It would be ideal if
the usage of organic solvents could be completely avoided, whileThis journal is ª The Royal Society of Chemistry 2011
Fig. 13 SEM photographs of the spray-dried microparticles fabricated
using different dopants before (A0, B0) and after (A1, B1) drug release
test: (A) R2.5C0.5(H) and (B) R2.5T0.5(H). (Scale bar of main picture:































































View Onlinestill enabling the regulation of the release profiles. Complex
materials consisting of blends of polymers or copolymers have
been developed previously to obtain the desired functionalities of
pharmaceutical particles.31 Herein, the drug release profiles were
tuned by different blending strategies of the precursors prior to
drying.
To investigate the effects of incorporating a hydrophilic
compound on the drug release rate, chitosan was chosen as the
model polymer. The high amount of amino groups on polymer
chains provided chitosan with good hydrophilic properties and
solubility in acidic medium. The microstructure of the spray-
dried microparticles was displayed in Fig. 7C. As shown in
Fig. 12, the incorporation of chitosan effectively increased the
drug release rate. Chitosan has been reported to trigger the drug
release for Eudragit RS beads and enhance the water uptake
for Eudragit RS films,32,33 consistent with the data reported
here. The characteristics of microparticles before and after drug
release test at pH 7.4 were compared (Fig. 13A0 and A1), with no
visible change observed in the particle morphology and surface
characteristics. Due to the pH dependent solubility of chitosan,
the release test was also performed in HCl solution (pH 1.2) to
simulate gastric fluid, as the pH closest to that of a human’s
stomach. Because of the fast release rate for these microparticles,
no noticeable distinction in the drug release rate was observed
with different release media. However, distinct surface charac-
teristic and inner structure of microparticles were observed after
the release test, due to chitosan solubility in the acidic condition
(ESI†, Fig. S4).
To enable drug release in a more controlled manner, a network
structure would be ideal to provide increasing drug diffusion
barriers. It had been reported that the acidic hydrolysis of TEOS
generated a rigid interpenetrating network (as illustrated in
Fig. 7D), which did not swell but could be degraded or eroded in
a release medium.34,35 As expected, the incorporation of TEOS
effectively slowed down the drug release rate (Fig. 12). The drug
release was completed after about 24 hours, accompanied with
a relatively sustained release rate at the initial stage. In addition,
the continuous degradation of silica network enhanced drug
diffusion and compensated the diminished drug accessibility,Fig. 12 Cumulative in vitro release of VB12 from the spray-dried
microparticles fabricated using different dopants.
This journal is ª The Royal Society of Chemistry 2011with a relatively faster drug release rate achieved at the latter
stage compared with the other cases. SEM photographs of the
microparticles before and after the release tests clearly revealed
the degradation of the silica matrix (Fig. 13B0 and B1).
The analysis of the release data with the empirical equation
proposed by Peppas and Sahlin: (Mt/MN)¼ k1tm + k2t2m was also
conducted to further explain the drug release mechanisms from
the microparticles, where Mt/MN was the fraction of drug
released at time t, and k1, k2, and m were the respective costants
from best fit with the experimental data36 (ESI†, drug release
kinetics).
Conclusion
The design of uniform drug carriers via a continuous, one-step
particle formation process was demonstrated here, with under-
standing of the difference in physicochemical behaviors of the
excipients within aqueous and organic-based solvent systems to
control the drug release kinetics. The drug release rates of the
carriers could be adjusted in the absence of organic solvents, by
changing the drying temperature or incorporating different
dopants. The microparticles obtained were uniform with almost
100% drug loading efficiency, and virtually no limitation to the
range of excipients and drugs including heat sensitive materials
such as polymers or proteins, due to the relatively low temper-
ature range used. The strategy to control the release functionality
of microparticles from microstructures can be applied to other
materials with unique physicochemical behaviors under different
conditions such as pH-sensitive or thermal sensitive materials to
fabricate particles with unique microstructures and to tune the
release kinetics.
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